Considerations in the design of clinical trials for cognitive aging

Eric M. Reiman, Roberta Diaz Brinton, Russell Katz, Ronald C. Petersen, Selam Negash, Dan Mungas, Paul S. Aisen

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


What will it take to develop interventions for the treatment of age-related cognitive decline? Session V of the Summit provided perspectives on the design of clinical trials to evaluate promising but unproven interventions, and some of the steps needed to accelerate the discovery and evaluation of promising treatments. It considered strategies to further characterize the biological and cognitive changes associated with normal aging and their translation into the development of new treatments. It provided regulatory, scientific, and clinical perspectives about neurocognitive aging treatments, their potential benefits and risks, and the strategies and endpoints needed to evaluate them in the most rapid, rigorous, and clinically meaningful way. It considered lessons learned from the study of Alzheimer's disease, the promising roles of biomarkers in neurocognitive aging research, and ways to help galvanize the scientific study and treatment of neurocognitive aging.

Original languageEnglish (US)
Pages (from-to)766-772
Number of pages7
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume67 A
Issue number7
StatePublished - Jun 15 2012


  • Aging
  • Clinical trials
  • Cognition

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Considerations in the design of clinical trials for cognitive aging'. Together they form a unique fingerprint.

Cite this